Genmab — December 2017

[rex_pacis]

I read somewhere that the first data from solids will come autumn-18

[Legolas23]

Se, hvad ASH er forkortelsen af. R&D efterfølgende kan måske afsløre, hvilke måneder i 2018, hvor vi kan blive klogere på Darzalex i solide.

[JohnW]

Hvad lægger I i hans ordvalg "we don't have proof of concept there" ?

[OHW]

De unævnlige startede med netto køb men er nu tilbage, hvor vi kender dem. Nettosalget fortsætter.

[E_L]

onclive video
http://www.onclive.com/inside-oncology/pre-conference-heme2017/daratumumab-for-smoldering-myeloma - http://www.onclive.com/inside-oncology/pre-conference-heme2017/phase-3-data-for-relapsed-refractory-myeloma

[E_L]

John - that he thinks it is too early to judge, there is no proof yet that it will work. which is correct, until we see data.

[rex_pacis]

American Society of Hematology

[JohnW]

@E L so no proof that it doesn't work either.

[Mcjean]

Ty EL i have and account there but cant remember password and a bit lazy:-)

[E_L]

exactly! and there are clearly INDICATIONS that it will work, but it needs to go through the process...

[E_L]

lol Mcjean, ok then so I need to do the work for you???

[Mcjean]

Need more coffee .......yep u do:-)

[E_L]

haha

[Mcjean]

But didnt expect you to make a slidesshow or posters.........very impressive indeed

[Mcjean]

Joaquin could leran a little from JDW, he sound not very optimistic but maybe i overkill the sentence and the way he express himself.

[E_L]

J&J’s Darzalex set to shake up frontline treatment of multiple myeloma https://www.pharmaceutical-technology.com/comment/jjs-darzalex-set-shake-frontline-treatment-multiple-myeloma/ , addressing 1 of the questions i would hope to get a bit more clarity on during ASH; can D-VMP compete with VRD in the US? would be a nice positive short term

[mobbyduck1]

I am still afraid, that we will struggle, until we have a teach deal. 18 months ago, we had a large queue at the cashier??? and only 2 months ago, we had another promise, that we will see a tech deal in 2017, well there is very little time left. . It means so much not to disappoint the market, and we have done it over and over again, regarding these tech deals

[E_L]

Hang in there mobby; it is almost weekend, 2 whole days without falling prices!

[E_L]

Dr. Usmani has chosen Abstract 3110 as one of his favorites. This abstract is the use of Kyprolis, Revlimid, dex and daratumumab for newly diagnosed myeloma patients. https://www.myelomacrowd.org/ash-2017-myeloma-experts-favorite-ash-abstract-pick-dr-saad-usmani/

[kbsv]

the 12-month progression free survival rate was 95%